Biallelic SCN2A Gene Mutation Causing Early Infantile Epileptic Encephalopathy: Case Report and Review

Shahad AlSaif¹, Muhammad Umair² and Majid Alfadhel²,3

¹College of Medicine, King Saud bin Abdulaziz University for Health Science, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs (NGHA), Riyadh, Saudi Arabia. ²Medical Genomics Research Department, King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Science, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs (NGHA), Riyadh, Saudi Arabia. ³Division of Genetics, Department of Pediatrics, King Saud bin Abdulaziz University for Health Science, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs (NGHA), Riyadh, Saudi Arabia.

ABSTRACT: The voltage-gated sodium channel neuronal type 2 alpha subunit (Naᵥα1.2) encoded by the SCN2A gene causes early infantile epileptic encephalopathy (EIEE) inherited in an autosomal dominant manner. Clinically, it has variable presentations, ranging from benign familial infantile seizures (BFIS) to severe EIEE. Diagnosis is achieved through molecular DNA testing of the SCN2A gene. Herein, we report on a 30-month-old Saudi girl who presented on the fourth day of life with EIEE, normal brain magnetic resonance imaging (MRI), normal electroencephalography (EEG), and well-controlled seizures. Genetic investigation revealed a novel homozygous missense mutation (c.5242A > G; p.Asn1748Asp) in the SCN2A gene (NM_001040142.1). This is the first reported autosomal recessive inheritance of a disease allele in the SCN2A and therefore expands the molecular and inheritance spectrum of the SCN2A gene defects.

KEYWORDS: SCN2A, early infantile epileptic encephalopathy, benign familial infantile seizure, epilepsy, seizure, sodium channel

Introduction

The sodium channel neuronal type 2 alpha subunit (SCN2A) gene encodes the voltage-gated sodium channel Naᵥα1.2 which is mainly responsible for the generation of action potentials in excitable cells.¹ Any mutation that causes loss of function (LOF) or changes the secondary structure of the SCN2A protein might result in the disruption of the sodium channel function. This might cause loss or decreased excitability of the neuronal cells, which contributes to autism spectrum disorder, or might cause hyperexcitability of neuronal cells, which is characterized as infantile seizures.² However, LOF, which does not result in hyperexcitable neurons, can still cause severe phenotypes with seizures.³ Later in development, reduced excitability of unmyelinated cortical inhibitory neurons might lead to hyperexcitable cortical networks. Any pathogenesis due to SCN2A LOF might affect inhibitory/excitatory balance, which gives rise to seizures, neuropsychiatric disorders, and autism.³

The most common clinical presentation of SCN2A defect is the benign familial infantile seizures type 3 (BFIS3; MIM 607745), which is an autosomal dominant neurological disorder, characterized by apnea, cyanosis, and cluster seizures that occur over one or several days.⁴ The seizures are mostly focal, consisting of twitching of the limbs with the head turned, lips smacking, blinking of the eye, and staring episodes.⁵,⁶ Patients may also present secondary generalized seizures.⁶ Usually, seizures cease at the end of the first year of life, yet some continue to have seizures through adulthood without any subsequent abnormality in neurological development.⁵,⁶ Electroencephalography (EEG) and magnetic resonance imaging (MRI) in these patients have insignificant results. Another phenotype associated with SCN2A pathogenesis include the early infantile epileptic encephalopathy type 11 (EIEE11), having autosomal dominant inheritance of the neurological disease, exhibiting a more severe neurological manifestation.⁷,⁸ Patients with EIEE present early onset of infantile refractory seizures, which eventually lead to a marked delay in intellectual and motor development.⁷,⁹ Initially, patients may present features such as neonatal hypotonia that proceeds to partial seizure along with generalized refractory tonic-clonic seizures, which might further progress to Ohtahara and West syndromes.¹⁰,¹¹ Patients might exhibit dysphagia, dysarthria, excessive daytime sleepiness, disturbed visual contact, and in severe cases, paralysis.⁷,⁸,¹⁰ Brain MRI of these patients can show a variety of findings, with brain atrophy commonly reported.⁸,¹⁰,¹² As with MRI, EEG findings vary among patients, mostly showing hypsarrhythmia and focal or multifocal sharp waves.⁷,¹²

To our knowledge, all the previously reported cases of SCN2A gene defects are inherited in dominant heterozygous state or de novo state, and there is no previously reported case having an autosomal recessive inheritance having homozygous variant in the SCN2A gene. Herein, we report the first patient with a biallelic missense mutation in the SCN2A gene with an autosomal recessive inheritance.
Case Report

The patient is a 30-month-old Saudi girl born full term via elective cesarean section to first cousin parents with an uneventful pregnancy. She is the fourth child of her parents with three older siblings. At birth, she had a length of 48 cm (10th-25th centile), weight of 3 kg (10th-25th centile), head circumference (HC) of 34 cm (10th-25th centile), and Apgar scores of 9 and 10 at 1 and 5 minutes, respectively. After discharge at 4 days of age, she presented with neonatal seizures described as mouth and eye deviation and jerking movement of the upper and lower limbs for one minute. At 1 month of age, the proband was alert, awake, afebrile, and she was prescribed phenobarbital and phenytoin after initiating appropriate investigations, including septic work up, brain computed tomography (CT), lumber puncture, EEG, and MRI of the brain. A week later, patient seizures were determined to be controlled on phenytoin and phenobarbital, and she was discharged as a follow-up patient with the pediatric neurology department. Later, she presented with multiple emergency department (ED) visits complaining mainly of seizures ranging from blinking and spasmodic hiccups to classical tonic-clonic movement, upon which she was elected for admission for further investigation, including long-term EEG monitoring and genetic consultation. Abnormal EEG results led to the addition of levetiracetam to the previous regimen.

Follow-up examination

Other than the symptoms mentioned above, the patient is thriving appropriately for her age and has no other medical problems. On examination at 30 months of age, her measurements were as follows: height 87 cm (10th-25th centile), weight 12 kg (10th-25th centile), and HC 48 cm (25th-50th centile). The patient generally looks well; is awake, alert, and active; and is not dysmorphic, with normal tone and power and normal gait and coordination. She is vitally stable and has unremarkable central nervous system (CNS) and other system examination results. Multiple EEGs were performed, all with normal findings. Pediatric long-term monitoring (LTM) initially revealed abnormal sleep and awake readings, yet subsequent repeated LTM/EEGs were within normal limits. Brain MRI, abdominal ultrasound, cystourethrogram, renal ultrasound, auditory brainstem response, echocardiogram, and ophthalmology evaluations were normal. Complete blood count, serum drug and toxicity levels, renal profile, liver profile, and cerebrospinal fluid (CSF) assays for cell counts, protein, and glucose levels, stool and urine analyses were all normal.

Laboratory test

All of the following biochemical and genetic investigations were unremarkable: acylcarnitine profile, ammonia, lactic acid, creatine kinase, total homocysteine, urine amino acids, urine organic acids, coagulation profile, lipid profile, very long chain fatty acids, urine for creatine and guanidinoacetate, urine for purine and pyrimidines, chromosomes analysis, and comparative genomic hybridization (CGH) microarray.

Genetic and Molecular Analysis

Genomic DNA extraction

The present study was performed after the approval of institutional review board (IRB), followed by Helsinki protocols, and written informed consent was obtained from the patient’s parents to publish this case report. Genomic DNA was extracted using commercially available kit and quantified using standard methods.

Gene panel

Genetic testing with an EIEE gene panel (Centogene, Germany) identified a homozygous missense mutation (c.5242A>G; p.Asn1748Asp) in SCN2A (NM_001040142.1) located on chromosome 2q24.3.

Sanger sequencing

Segregation analysis of the identified homozygous variant was undertaken for both the parents, three siblings using standard methods, and showed that the parents and two siblings were heterozygous carriers, while one healthy sister is wild type.

The parents were comprehensively counseled regarding the genetic results, its mode of inheritance, and the recurrence risk of 25% in each pregnancy. The patient’s seizures are well controlled with phenobarbital and levetiracetam, and she has normal development with no deterioration or complications.

Discussion

The present report describes the first documented homozygous SCN2A mutation causing EIEE in autosomal recessive manner, as all previously reported patients were reported having heterozygous SCN2A variant in either dominant or de novo fashion. The pathogenicity of the variant (c.5242A>G; p.Asn1748Asp) reported here is supported by segregation within the family. Furthermore, the variant is rare and not described in homozygous or heterozygous state in the Exome Aggregation Consortium (ExAC), Genome Aggregation Database (gnomAD), Exome Variant Server (EVS), or 1000 Genomes Project and in 2000 in-house ethnically matched exomes. In addition, computational analysis tools, including PolyPhen, SIFT, MutationTaster, and phyloP, predict this variant to be most likely damaging.

Pathogenic heterozygous and de novo mutations in the SCN2A gene have been reported with two causes: EIEE11 (MIM 613721) and BFIS3 (MIM 607745). Table 1 summarizes the patients reported to have EIEE due to either heterozygous or de novo mutations within the SCN2A gene.7,12–90
Table 1. Comparison of the current case with previously reported cases having SCN2A gene defects.\textsuperscript{7,12–90}

|                      | PREVIOUSLY REPORTED CASES | PRESENT CASE | %     |
|----------------------|---------------------------|--------------|-------|
| Number of cases      | 290                       | 1            | 291   |
| Origin               | Denmark (71), Canada (8), China (28), England (11), Czech Republic (2), Turkey (1), Switzerland (5), Australia (40), Taiwan (2), Italy (15), U.S.A (56), Japan (22), UK (7), Sweden (20), and France (2) | Saudi Arabia | Most common from Denmark |
| Type of inheritance  | Heterozygous, AD          | Homozygous, AR |       |
| Neurological symptoms|                           |              |       |
| Family history of seizures | 139                     | Negative    | 47.9  |
| Type of seizures     | Benign familial infantile seizures, benign familial neonatal epilepsy, childhood seizures, early infantile epileptic encephalopathy, epileptic encephalopathy, episodic ataxia, febrile seizures, infantile epilepsy, infantile spasms, intractable epilepsy, migrating focal seizures of infancy, neonatal epileptic encephalopathy, neonatal seizures, and recurrent encephalopathy (253) | Early infantile epileptic encephalopathy | 87.24 |
| Autism               | 62                        | Not observed | 21.3  |
| Migrating focal seizures of infancy | 19                       | Not observed | 6.55  |
| Paroxysmal ataxia in toddler | 13                      | Not observed | 4.48  |
| Ohtahara syndrome    | 14                        | Not observed | 4.82  |
| West syndrome        | 4                         | Not observed | 1.37  |
| Lennox-Gastaut syndrome | 2                       | Not observed | 0.68  |
| Normal               | 42                        | 1            | 14.48 |
| Developmental delay  | 91                        | Not observed | 31.37 |
| Neurological examination|                         |              |       |
| Dysmorphic features  | 48                        | Not observed | 16.55 |
| Hypotonia            | 72                        | 1            | 24.82 |
| Ataxic gait          | 23                        | 1            | 7.93  |
| Spasticity           | 9                         | 1            | 3.10  |
| Electroencephalogram findings (187 of 290) | | | |
| Normal               | 37                        | 1            | 12.75 |
| Abnormal (EEG) findings | Extremely variable and include multifocal poly spike activity, hypsarrhythmia, burst suppression pattern, and diffuse slowing (123) | Normal | 42.41 |
| MRI findings (175 of 290) | | | |
| Normal               | 56                        | Normal       | 19.31 |
| Cerebral atrophy     | 81                        | Not observed | 27.93 |
| Hypoplastic corpus callosum | 39                      | Not observed | 13.44 |
| Cerebellar atrophy   | 53                        | Not observed | 18.27 |
| Lesions in right parietal/temporal/occipital lobes | 9 | Not observed | 3.10 |
| Cortical/subcortical edema | 7                       | Not observed | 2.41  |
| Diffuse abnormalities of white matter | 15                     | Not observed | 5.17  |

(Continued)
According to Human Gene Mutation Database (HGMD, 2018), 268 mutations have been reported in the \( \text{SCN2A} \) gene presenting diverse phenotypes (Table 2). We identified a total of 290 cases having heterozygous or de novo \( \text{SCN2A} \) gene mutations in the literature survey. Approximately 87.24% of cases reported several types of seizures, including BFIS, benign familial neonatal epilepsy, refractory neonatal epilepsy, infantile spasms, episodic ataxia, acute encephalopathy, recurrent encephalopathy, and EIEE, as observed in the present case. Other reported symptoms included autism (21.3%), severe pulmonary emphysema (4.48%), migrating focal seizures of infancy (6.55%), paroxysmal ataxia in toddlers (4.48%), developmental delay (31.37%), Ohtahara syndrome (4.85%), West syndrome (1.37%), and Lennox-Gastaut syndrome (0.68%). The ages of symptom onset ranged from a few hours after birth up to 6.6 years. None of the previously reported cases were documented with parental consanguinity as described in our case. Regarding clinical features, 14.48% had normal features, 24.82% presented with hypotonia, 7.93% with ataxic gait, and 3.10% with spasticity. EEGs showed normal findings in 12.75%, including the current patient. Brain MRI was normal in our patient and in 19.31% of cases in literature. Moreover, 27.93% demonstrated cerebral atrophy, 13.44% showed hypoplastic corpus callosum, 18.27% suffered from cerebellar atrophy, and 3.10% had lesions in the right parietal/temporal/occipital lobes. The following features were observed in 5.86% of cases such as cortical/subcortical edema, diffuse abnormalities of white matter, lack of differentiation between cortex and subcortical layers with pachygyria and anomalies of the cortical gyration, and immature myelination at the bilateral periventricular areas. Up to 47.90% of cases were reported to have a family history of seizures; however, the current case had a negative family history of seizures. In total, 36 (12.41%) of cases reported so far were deceased, and the age at death ranged from 5 to 75 years old.

Patient with de novo or dominant heterozygous \( \text{SCN2A} \) gene mutations display epileptic phenotypes. Thus, it is not surprising that patients with a homozygous \( \text{SCN2A} \) mutation also have an epileptic phenotype. Despite the aforementioned fact, the importance of the current case relies on the following: first, this alerts the clinician to consider \( \text{SCN2A} \) gene defects in any patient presenting with seizures regardless of their family history, suggesting an autosomal recessive or autosomal dominant pattern. Second, it is confirmed that an autosomal recessive pattern may lead to more severe presentation, which is early neonatal epileptic encephalopathy rather than ataxia and autism in heterozygous probands.

Mutations in the \( \text{SCN2A} \) gene have a strong association with the manifestation of numerous types of seizures, along with other clinical characteristics, including autism, cerebral atrophy, recurrent encephalopathy, and EIEE, as observed in the present case. Other reported symptoms included autism (21.3%), severe pulmonary emphysema (4.48%), migrating focal seizures of infancy (6.55%), paroxysmal ataxia in toddlers (4.48%), developmental delay (31.37%), Ohtahara syndrome (4.85%), West syndrome (1.37%), and Lennox-Gastaut syndrome (0.68%). The ages of symptom onset ranged from a few hours after birth up to 6.6 years. None of the previously reported cases were documented with parental consanguinity as described in our case. Regarding clinical features, 14.48% had normal features, 24.82% presented with hypotonia, 7.93% with ataxic gait, and 3.10% with spasticity. EEGs showed normal findings in 12.75%, including the current patient. Brain MRI was normal in our patient and in 19.31% of cases in literature. Moreover, 27.93% demonstrated cerebral atrophy, 13.44% showed hypoplastic corpus callosum, 18.27% suffered from cerebellar atrophy, and 3.10% had lesions in the right parietal/temporal/occipital lobes. The following features were observed in 5.86% of cases such as cortical/subcortical edema, diffuse abnormalities of white matter, lack of differentiation between cortex and subcortical layers with pachygyria and anomalies of the cortical gyration, and immature myelination at the bilateral periventricular areas. Up to 47.90% of cases were reported to have a family history of seizures; however, the current case had a negative family history of seizures. In total, 36 (12.41%) of cases reported so far were deceased, and the age at death ranged from 5 to 75 years old.

Patient with de novo or dominant heterozygous \( \text{SCN2A} \) gene mutations display epileptic phenotypes. Thus, it is not surprising that patients with a homozygous \( \text{SCN2A} \) mutation also have an epileptic phenotype. Despite the aforementioned fact, the importance of the current case relies on the following: first, this alerts the clinician to consider \( \text{SCN2A} \) gene defects in any patient presenting with seizures regardless of their family history, suggesting an autosomal recessive or autosomal dominant pattern. Second, it is confirmed that an autosomal recessive pattern may lead to more severe presentation, which is early neonatal epileptic encephalopathy rather than ataxia and autism in heterozygous probands.

Mutations in the \( \text{SCN2A} \) gene have a strong association with the manifestation of numerous types of seizures, along with other clinical characteristics, including autism, pulmonary emphysema, paroxysmal ataxia in toddlers, and Ohtahara syndrome. However, mutations in the \( \text{SCN1A}, \text{SCN1B}, \text{SCN8A}, \) or \( \text{SCN9A} \) genes also appear to be related to the expression of seizures. Here, we identified a novel homozygous missense mutation in the \( \text{SCN2A} \) causing EIEE; yet heterozygous \( \text{SCN2A} \) mutations can cause severe epileptic phenotypes, especially when they are de novo. Therefore, clinicians should keep in mind the \( \text{SCN2A} \) gene heterogeneity. This is also true for mutations in the \( \text{SCN1A} \) gene, with de novo mutations causing
the severe Dravet syndrome. Similarly, mutations in the SCN9A gene have been associated with pain disorders and suggested as a genetic modifier for the Dravet syndrome, thus considered as a susceptible gene. Moreover, SCN9A mutations are also inherited dominantly and associated with more severe manifestations of EIEE and BFIS. Homozygous SCN1B mutations have been shown to cause a clinical phenotype of Dravet syndrome, while heterozygous mutations in autosomal dominant cases have been associated with generalized epilepsy and febrile seizures. The limitation of the current study is being the only homozygous case described in the family and current literature making a firm inference of pathogenicity impossible; therefore, further homozygous reported cases with similar phenotype would confirm such conclusion.

Conclusion
We report the first case of a homozygous SCN2A gene mutation in a female toddler from Saudi Arabia having hallmark features of EIEE in autosomal recessive manner. In addition, we describe a novel mutation that increased the mutational spectrum of SCN2A-associated pathogenesis. This finding expands the molecular and inheritance spectrum of SCN2A gene defects.

Acknowledgements
The authors are grateful to the patient and her family for their genuine support.

Author Contributions
SAS wrote the first draft and edited subsequent versions. MAF and MU wrote the final draft, edited the subsequent version, and contributed to the clinical diagnosis and management of the patients. All authors have read and approved the final draft of the manuscript.

ORCID iD
Majid Alfadhel https://orcid.org/0000-0002-9427-7240

REFERENCES
1. Ahmed CM, Ware DH, Lee SC, et al. Primary structure, chromosomal localization, and functional expression of a voltage-gated sodium channel from human brain. Proc Natl Acad Sci U S A. 1992;89:8220–8224.
2. Ben-Shalom R, Keeshen CM, Berrios KN, An JY, Sanders SJ, Bender KJ. Opposing effects on Nav1.2 function underlie differences between SCN2A variants observed in individuals with autism spectrum disorder or infantile seizures. Biol Psychiatry. 2017;82:224–232. doi:10.1016/j.biopsych.2017.01.009.
3. Wolf M, Johannesen KM, Hedrich UBS, et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain. 2017;140:1316–1336. doi:10.1093/brain/awx054.
4. Shevell MI, Sinclair DB, Metrakos K. Benign familial neonatal seizures: clinical and electroencephalographic characteristics. Pediatr Neurol. 1986;2:272–275.
5. Kaplan RE, Lacey DJ. Benign familial neonatal-infantile seizures. Am J Med Genet. 1983;16:595–599. doi:10.1002/ajmg.1320160417.
6. Berkovic SF, Heron SE, Giordano I, et al. Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. Ann Neurol. 2004;55:550–557. doi:10.1002/ana.20292.
7. Ogwara I, Ito K, Sawaihi Y, et al. De novo mutations of voltage-gated sodium channel alpha II gene SCN2A in intractable epilepsies. Neurology. 2009;73:1046–1053. doi:10.1212/WNL.0b013e3181f9eb9c.
32. Leach EL, van Karnebeek CD, Townsend KN, Tarallo-Graorac M, Hokie J, Gibson WT. Episodic ataxia associated with a de novo SCN2A mutation. Eur J Pediatr Neurol. 2016;20:772–776. doi:10.1016/j.ejpn.2016.05.020.

33. Bernardo S, Marchionni E, Prudente S, et al. Unusual association of SCN2A with severe cortical dysplasia detected by prenatal MRI. Eur J Pediatr Neurol. 2017;21:587–590. doi:10.1016/j.ejpn.2017.01.014.

34. Leach EL, van Karnebeek CD, Townsend KN, Tarailo-Graovac M, Hukin J, Bhanot S. Progressive ACVAs and delayed development. Clin Genet. 2017;91:106–110. doi:10.1111/cge.12797.

35. Schwarz N, Hahn A, Bast T, et al. Mutations in the sodium channel gene SCN2A cause neonatal epilepsy with late-onset episodic ataxia. J Neurol. 2016;263:334–343. doi:10.1007/s00415-015-7984-0.

36. Depienne C, Trouillard O, Gourfinkel-An I, et al. Mechanisms for variable expression in SCN1A mutations. Hum Mol Genet. 2017;26:4131–4140. doi:10.1093/hmg/ddx323.

37. Depienne C, Trouillard O, Saint-Martin C, et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome. J Med Genet. 2010;47:840–844. doi:10.1136/jmg.2009.074328.

38. Depienne C, Trouillard O, Saint-Martin C, et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet. 2009;46:183–191. doi:10.1136/jmg.2008.062323.

39. Riva D, Vago C, Pantaleoni C, Bulgheroni S, Mantegazza M, Franceschetti S, Progressi AC, Vezzani A. De novo SCN2A truncations and different epileptic phenotypes. Am J Med Genet A. 2014;169A:2339–2345. doi:10.1002/ajmg.a.33029.

40. Heron SE, Scheffer IE, Iona X, et al. De novo SCN2A mutations in Dravet syndrome and related epileptic encephalopathies are largely of paternal origin. J Med Genet. 2012;49:502–510. doi:10.1136/jmg.2011.088403.

41. Li J, Le JF, Liu X, Chang JS, Huang KL. SCN2A mutation in an infant presenting with migrating focal seizures and infantile spasm response to a ketogenic diet. Brain Dev. 2018;40:724–727. doi:10.1016/j.braindev.2018.03.005.

42. Shi X, Yasumoto S, Nakagawa E, Fukauka T, Uchiya I, Hirose S. Missense mutation of the sodium channel gene SCN2A causes Dravet Syndrome. Brain Dev. 2009;31:758–762. doi:10.1016/j.braindev.2009.08.009.

43. Hettenius E, Heron SE, Grinton BE, et al. SCN2A mutations and benign familial neonatal-infantile seizures: the phenotypic spectrum. Epilepsia. 2007;48:1138–1142.
81. Matalon D, Goldberg E, Medne L, Marsh ED. Confirming an expanded spectrum of SCN2A mutations: a case series. *Epileptic Disord*. 2014;16:13–18. doi:10.1684/epd.2014.0641.

82. Soden SE, Saunders CJ, Willig LK, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. *Sci Transl Med*. 2014;6:265ra168. doi:10.1126/scitranslmed.3010076.

83. Srivastava S, Cohen JS, Vernon H, et al. Clinical whole exome sequencing in child neurology practice. *Ann Neurol*. 2014;75:473–483. doi:10.1002/ana.24251.

84. Stanek D, Lasszuthova P, Sterbova K, et al. Detection rate of causal variants in severe childhood epilepsy is highest in patients with seizure onset within the first four weeks of life. *Orphanet J Rare Dis*. 2018;13:71. doi:10.1186/s13023-018-0812-8.

85. Trujillano D, Bertoli-Avella AM, Kumar Kandaswamy K, et al. Clinical exome sequencing: results from 2819 samples reflecting 1000 families. *Eur J Hum Genet*. 2017;25:176–182. doi:10.1038/ejhg.2016.146.

86. Trump N, McTague A, Brittain H, et al. Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis. *J Med Genet*. 2016;53:310–317. doi:10.1136/jmedgenet-2015-103263.

87. Wang T, Guo H, Xiong B, et al. De novo genic mutations among a Chinese autism spectrum disorder cohort. *Nat Commun*. 2016;7:13316. doi:10.1038/ncomms13316.

88. Zeng Q, Yang X, Zhang J, et al. Genetic analysis of benign familial epilepsies in the first year of life in a Chinese cohort. *J Hum Genet*. 2018;63:9–18. doi:10.1038/s10038-017-0359-x.

89. Zhang Q, Li J, Zhao Y, Bao X, Wei L, Wang J. Gene mutation analysis of 175 Chinese patients with early-onset epileptic encephalopathy. *Clin Genet*. 2017;91:717–724. doi:10.1111/cge.12901.

90. Zhu X, Padmanabhan R, Copeland B, et al. A case-control collapsing analysis identifies epilepsy genes implicated in trio sequencing studies focused on de novo mutations. *PLoS Genet*. 2017;13:e1007104. doi:10.1371/journal.pgen.1007104.